Quest Diagnostics Expands Alzheimer's Blood Testing Portfolio with FDA-Cleared Roche pTau217 Assay
Event summary
- Quest Diagnostics to offer FDA-cleared Roche pTau217 blood test for Alzheimer's assessment in Q4 2026
- New multi-biomarker AD-Detect panel achieves 10% indeterminate rate, below industry benchmarks
- Test results align with Alzheimer's Association guidelines for diagnostic accuracy
- Blood-based testing proven more cost-effective than PET-CT scans for Alzheimer's evaluation
The big picture
Quest Diagnostics' expansion of its AD-Detect portfolio reflects the growing shift toward blood-based diagnostics for Alzheimer's, which offer cost and accessibility advantages over traditional methods. The FDA clearance of Roche's pTau217 test validates this approach, potentially accelerating industry adoption. With approximately 2,000 patient service centers, Quest is well-positioned to scale this technology nationwide.
What we're watching
- Market Adoption
- How quickly physicians will integrate the FDA-cleared pTau217 test into standard diagnostic protocols
- Competitive Positioning
- Whether Quest can maintain leadership in Alzheimer's blood testing as competitors develop similar offerings
- Regulatory Expansion
- The pace at which additional blood biomarkers receive FDA clearance for Alzheimer's diagnosis
Related topics